Access the full text.
Sign up today, get DeepDyve free for 14 days.
Marcel Kloppenburg, F. Mildner, Maria Kasseroler, D. Dejaco, A. Amann (2020)
Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSSC)memo - Magazine of European Medical Oncology, 13
C. Wagner (2020)
Nutritional management during treatment for head and neck cancermemo - Magazine of European Medical Oncology
E. Sturgis, Robert Miller (1995)
Second Primary Malignancies in the Head and Neck Cancer PatientAnnals of Otology, Rhinology & Laryngology, 104
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, David Forman (2011)
Global Cancer Statistics
M. Tornesello, F. Perri, L. Buonaguro, F. Ionna, F. Buonaguro, F. Caponigro (2014)
HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches.Cancer letters, 351 2
A. Strobl, Maximilian Hartl, M. Burian (2020)
Transoral robotic surgery in head and neck cancermemo - Magazine of European Medical Oncology, 13
W. Gradishar, Benjamin Anderson, Ron Balassanian, Sarah Blair, H. Burstein, Amy Cyr, Anthony Elias, William Farrar, Andres Forero, Sharon Giordano, Matthew Goetz, Lori Goldstein, S. Isakoff, Janice Lyons, P. Marcom, I. Mayer, B. McCormick, Meena Moran, Ruth O'Regan, Sameer Patel, Lori Pierce, Elizabeth Reed, K. Salerno, L. Schwartzberg, Amy Sitapati, Karen Smith, Mary Smith, H. Soliman, G. Somlo, M. Telli, John Ward, Dorothy Shead, Rashmi Kumar (2017)
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.Journal of the National Comprehensive Cancer Network : JNCCN, 15 4
D. Pfister, K. Ang, D. Brizel, B. Burtness, P. Busse, J. Caudell, A. Cmelak, A. Colevas, F. Dunphy, D. Eisele, J. Gilbert, M. Gillison, R. Haddad, B. Haughey, W. Hicks, Y. Hitchcock, M. Kies, W. Lydiatt, E. Maghami, R. Martins, T. Mccaffrey, B. Mittal, H. Pinto, J. Ridge, S. Samant, D. Schuller, Jatin Shah, S. Spencer, R. Weber, G. Wolf, F. Worden, S. Yom, Nicole Mcmillian, M. Hughes (2013)
Head and Neck Cancers, Version 2.2013Journal of The National Comprehensive Cancer Network, 11
C. Leemans, R. Tiwari, J. Nauta, I. Waal, G. Snow (1994)
Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factorCancer, 73
C. Minichsdorfer (2020)
Systemic therapy for metastatic salivary gland tumors—challenges and novel conceptsmemo - Magazine of European Medical Oncology
N. Allen, L. Anderson, F. Beland, J. Benichou, V. Beral, K. Bloomfield, P. Brooks, Lin Cai, Sung-il Cho, D. Crabb, P. Eriksson, S. Gapstur, G. Gmel, Liudvika Griciūte, S. Kono, D. Lachenmeier, C. Vecchia, M. Marques, A. Miller, J. Rehm, Nina Rehn-Mendoza, Ivan Rusyn, H. Seitz, E. Weiderpass, W. Willett, A. Yokoyama, Zuo‐Feng Zhang, A. Huici-Montagud, A. Altieri, R. Baan, S. Balbo, J. Berthiller, V. Bouvard, P. Brennan, V. Cogliano, F. Ghissassi, P. Ferrari, S. Franceschi, N. Gaudin, Y. Grosse, M. Hashibe, F. Islami, Y. Lee, M. Marron, Jane Mitchell, N. Napalkov, B. Secretan, K. Straif, W. Tong, S. Egraz, Michel Javin, Brigitte Kajo, M. Lézère, Helene Lorenzen-Augros, L. Benbrahim-Tallaa, Crystal Freeman, N. Guha, Laurent Galichet, Anne Hameau, Sylvia Moutinho, D. Russell (2010)
Alcohol consumption and ethyl carbamate.IARC monographs on the evaluation of carcinogenic risks to humans, 96
humAn cArcinogens, peRsonAl hAbIts, Iarc Monographs (2012)
iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns
S. Marur, A. Forastiere (2008)
Head and neck cancer: changing epidemiology, diagnosis, and treatment.Mayo Clinic proceedings, 83 4
P. Georg (2020)
Particle therapy in head and neck cancer—expanding therapeutic optionsmemo - Magazine of European Medical Oncology
J. Vermorken, P. Specenier (2010)
Optimal treatment for recurrent/metastatic head and neck cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 7
editorial memo (2020) 13:359–360 https://doi.org/10.1007/s12254-020-00656-3 Gabriele Gamerith · Thorsten Fuereder © Springer-Verlag GmbH Austria, part of Springer Nature 2020 Head and neck (HNC) is the tenth most common can- For tumors, however, which are located near the cer worldwide with over 650,000 new cases per year skull base or in a previously irradiated field, particle [1–3]. The major risk factors for development of squa- therapy employing protons can provide a novel treat- mous cell HNC comprise alcohol and tobacco con- ment option accompanied with reduced side effects sumption [4]. During the last few decades human compared to conventional photon therapy. In addi- papilloma virus (HPV) infection has been identified tion to protons, carbon ions recently entered the stage to contribute to the development of oropharyngeal providing benefits for the treatment of radioresistant HNC in a younger subgroup of patients [5]. This histologies such as adenoid cystic carcinomas. population shows a more favorable prognosis com- Despite the improvements outlined above, recur- pared to HPV-negative disease [5]. Standard treatment rence rates of stage III/IV disease after curative ther- options for HNC independent of HPV status include apy is about 50% in the first 2 years of follow-up [6, 7]. surgery, standard
memo - Magazine of European Medical Oncology – Springer Journals
Published: Dec 1, 2020
Keywords: oncology; medicine/public health, general
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.